^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | Tasigna (nilotinib) (Bcr-abl tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Imatinib...and second generation TKIs (dasatinib..., nilotinib..., and bosutinib...) are all appropriate options for first-line TKI therapy for patients with CP-CML across all risk scores.
